Bioassay Survey 2006–2007 Cell-Based Bioassays in the Biopharmaceutical Industry

whitePaper | April 16, 2020

Over the past two years, the pharmacy industry has seen unprecedented increases in the prices of generic drugs, causing unexpected cost increases for payers and consumers, and spurring an investigation by the United States Congress. High generic drug prices have had an adverse effect on almost everyone in the pharmaceutical supply chain. Consumers face higher co-pays and prices and health plans are dealing with higher drug spend. Physicians are finding the need to prescribe alternative drug therapies while dealing with angry patients.

whitePaper | December 12, 2019

X-ray inspection of pharmaceutical products and over-the-counter (OTC) medications are steadily increasing in use as pharmaceutical manufacturers worldwide strive to safeguard their brand reputations, protect consumers' welfare and comply with national and international regulations and legislation.

whitePaper | December 14, 2022

When the regulatory hammer came down on pharmaceutical and life sciences (PLS) companies in the 2010s, it introduced new complexities for these businesses.

whitePaper | October 7, 2022

The Drug Supply Chain Security Act is one component of the DQSA. This particular act requires the FDA to implement a national track-and-trace system by which manufacturers must affix product identifiers (barcodes) to each package of product that is introduced into the supply chain.

whitePaper | June 15, 2022

To date, therapeutic advances in treating central nervous system (CNS) disorders have been incremental at best. As the global population increases and older demographics begin to make up a disproportionately larger percentage,

whitePaper | April 26, 2022

The prevalence of communicable and non-communicable diseases are increasing worldwide, placing considerable demand on public health systems and driving a necessity to develop more effective targeted therapies.